Abarceo Pharma

Abarceo Pharma

Verified
Developing small molecule technology platform for the treatment of mitochondrial dysfunction, with an initial focus on T2D.

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
EUR20182019202020212022
Profit00000000000000000000
% profit margin-(23 %)(50 %)--
EV / revenue00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x
R&D budget00000000000000000000
  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor

$0.0

round
investor

$0.0

round
investor

$0.0

round
investor

$0.0

round
N/A

$0.0

round
N/A

SEK22.0m

Seed
Total Funding000k

Recent News about Abarceo Pharma

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.